Targeting angiogenesis: A novel, rational therapeutic approach for non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 50, Issue 5, 2009, Pages 679-681

  Ruan, Jia ^a   Leonard, John ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; RITUXIMAB; THALIDOMIDE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VINCRISTINE SULFATE;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; B CELL LYMPHOMA; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE MARKER; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; HYPERTENSION; IMMUNOMODULATION; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, NON-HODGKIN; NEOVASCULARIZATION, PATHOLOGIC;

EID: 68449102962     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902893835     Document Type: Note

References (11)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-573.
2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009;20:413-424.
4. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. New Engl J Med 2004;351:2159-2169.
5. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
6. Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper A, Coleman M, et al. The magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:5622-5631.
7. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
8. Stopeck AT, Unger ML, Rimsza LM, Bellamy WT, Iannone M, Persky DO, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non- Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009;50:728-735.
9. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin Invest 2003;112:1142-1151.
10. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. NatMed2006;12:557-567. [erratum appears in NatMed 2006;12:978].
11. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006;47:998-1005.